# Junta clínica — PT-pseudo_ac1dc724676e (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_ac1dc724676e",
  "pid": "PT-pseudo_ac1dc724676e",
  "task": 1,
  "psa": 7.0,
  "age": 76,
  "months": 3,
  "pirads": "5",
  "psad": 0.07,
  "psav": 1.23,
  "psap": 6.0,
  "vol": 94.53,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.7873657,
  "medhx": "Osteoarthritis",
  "meds": "paracetamol PRN",
  "notes": "PSA 7 ng/mL. PI-RADS 5. PSAD 0.07. Prostate volume 95 mL. DRE nodus. csPCa 0.79.",
  "pmhx": [
    "Osteoarthritis"
  ],
  "allergies": [],
  "vitals": {
    "weight": "96 kg",
    "height": "175 cm",
    "bmi": "31.3",
    "bp": "115/66 mmHg",
    "hr": "65 bpm",
    "smoking": "Non-smoker",
    "last_dental": "2 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "26 Feb 2025",
  "enc_ref": "Dr. P. van Dijk (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical review requested after multiparametric MRI revealed a PI-RADS 5 lesion and earlier biopsy results returned Positive."
    },
    {
      "s": "History",
      "t": "Surveillance protocols and lower urinary tract symptom oversight have guided care for an extended period. He is a 76-year-old retired mechanical engineer, Widowed, and Lives with partner. A Non-smoker, he sustains a rigorous routine involving twenty-kilometre cycling sessions twice weekly, alongside a weekly alcohol intake of seven units. His lower urinary tract symptoms are pronounced, registering an IPSS score of 30 from 35. Concurrent osteoarthritis is managed with paracetamol PRN. Apart from a recent podiatry visit and a stable right knee, his systemic health remains unchanged with no new complaints reported."
    },
    {
      "s": "Physical examination",
      "t": "Nodus DRE: The prostate exhibits asymmetric enlargement with a firm, irregular nodule localized to the left peripheral zone. Abdominal and cardiovascular assessments yield normal results. Vital parameters remain steady at 115/66 mmHg, with a pulse of 65 beats per minute."
    }
  ],
  "occupation": "retired mechanical engineer",
  "marital": "Widowed",
  "living": "Lives with partner",
  "next_of_kin": "Sibling (brother)",
  "recent_other": [
    "Podiatry — routine foot care"
  ],
  "alcohol": "7 units / week",
  "exercise": "Cycling 2x/week, ~20 km",
  "ipss": "IPSS score: 30/35 (severe LUTS)",
  "admin": "Interpreter: not required. Consent for data use: signed.",
  "mri_hospital": "Ziekenhuis Gelderse Vallei (Ede)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_ac1dc724676e
Task: 1

Encounter: Urology - outpatient on 26 Feb 2025.
Referrer: Dr. P. van Dijk (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 76-year-old male
  - PSA: 7.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.07 ng/mL²
  - PSA velocity: 1.23 ng/mL/yr
  - Prior PSA: 6.0 ng/mL
  - Prostate volume: 94.53 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7873657 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Osteoarthritis
  - Problem list / PMHx: Osteoarthritis
  - Current medication: paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 7 ng/mL. PI-RADS 5. PSAD 0.07. Prostate volume 95 mL. DRE nodus. csPCa 0.79.

Vitals: weight 96 kg, height 175 cm, BMI 31.3, BP 115/66 mmHg, HR 65 bpm. Smoking: Non-smoker.

Chief complaint: Clinical review requested after multiparametric MRI revealed a PI-RADS 5 lesion and earlier biopsy results returned Positive.

History: Surveillance protocols and lower urinary tract symptom oversight have guided care for an extended period. He is a 76-year-old retired mechanical engineer, Widowed, and Lives with partner. A Non-smoker, he sustains a rigorous routine involving twenty-kilometre cycling sessions twice weekly, alongside a weekly alcohol intake of seven units. His lower urinary tract symptoms are pronounced, registering an IPSS score of 30 from 35. Concurrent osteoarthritis is managed with paracetamol PRN. Apart from a recent podiatry visit and a stable right knee, his systemic health remains unchanged with no new complaints reported.

Physical examination: Nodus DRE: The prostate exhibits asymmetric enlargement with a firm, irregular nodule localized to the left peripheral zone. Abdominal and cardiovascular assessments yield normal results. Vital parameters remain steady at 115/66 mmHg, with a pulse of 65 beats per minute.

Patient info: retired mechanical engineer; Widowed; Lives with partner.
Next of kin: Sibling (brother).

Lifestyle: alcohol 7 units / week; exercise Cycling 2x/week, ~20 km; IPSS score: 30/35 (severe LUTS).

Recent other appointments: Podiatry — routine foot care.
Admin: Interpreter: not required. Consent for data use: signed.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.42
  uncertainty  +/- 0.11 epistemic (95% band 0.21-0.64); among patients I cannot tell apart the outcome was 0.98 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.46: PI-RADS 5, PSA 4.2, PSAD 0.06, age 67, DRE Nodus -> DEFER (uncertain). He wrote: "Need to know if the lesion has grown or if it is stabile."
  2. distance 1.82: PI-RADS 5, PSA 8.6, PSAD 0.202, age 68, DRE Nodus -> BIOPSY (clear). He wrote: "Patient reasonable to discuss curative treatment with (age 68, no very dramatic comorbidity, unfavorable intermediate risk disease). Considering he chose not curative tr…"
  3. distance 1.82: PI-RADS 5, PSA 6.9, PSAD 0.171, age 67, DRE Nodus -> DEFER (borderline). He wrote: "Need to know if the P5 lesion has grown in size. If not no biopsy."

PRECEDENT: DEFER (weighted vote 0.31 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline discusses using PI-RADS scores to guide the decision to perform a biopsy. It states that a PI-RADS threshold of $\ge 3$ is used to trigger biopsy, at the cost of missing a small number of mainly ISUP GG 2 cancers, especially in biopsy-naïve patients or in highly selected populations with a high prevalence of csPCa.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I disagree with the suggestion of no biopsy because the guideline suggests a PI-RADS $\ge 3$ threshold is used to trigger biopsy, and this patient has a PI-RADS 5 lesion. EXPERT-LIBRARY, the precedents suggest a mixed approach, with some cases leading to deferral and others to biopsy, indicating that the panel variables alone do not settle the decision.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA trend: the guideline does not provide a specific threshold for PSA trend in this context, so the conference must establish its relevance.
laboratory_results - the laboratory results: the guideline links PSA density to risk-adapted biopsy decisions, which is relevant given this patient's PSAD of 0.07.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on establishing the grade of the prior biopsy and the relevance of the PSA trend according to the EAU guidelines.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine whether the lesion is compared against an earlier study.
  psa_trend (get_psa_trend) -> Establish the relevance of the PSA trend in this context.
  previous_notes (get_previous_notes) -> Determine the grade of the prior biopsy and surveillance status.
  laboratory_results (get_lab_results) -> Determine the relevance of PSA density given the PSAD of 0.07.

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the grade (Gleason/ISUP) of the prior biopsy?
  Q2. Does the PI-RADS 5 lesion in the radiology report represent a new or larger lesion compared to an earlier study?
  Q3. What is the relevance of the PSA trend in this context?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: size and zone of the index lesion, as the report words it: "discrete hypointense focus within the left peripheral zone, spanning from the base toward the mid-gland at roughly 18 mm."

psa_trend
The relevance of the PSA trend in this context: The trend shows a rise from 2.5 ng/mL (Feb 2024) to 7.0 ng/mL (Feb 2025), indicating a rising trend.

previous_notes
PRIOR GRADE: not recorded
BIOPSY SESSIONS: not recorded
SURVEILLANCE: Surveillance protocols and lower urinary tract symptom oversight have guided care for an extended period.
TREATMENT: none recorded

laboratory_results
The relevance of PSA density given the PSAD of 0.07: The laboratory results show a PSA density of 0.07 ng/mL/mL, which is relevant given the PSAD of 0.07.

WHAT I DID NOT OPEN
family-history of prostate cancer (anamnesis) because the previous notes already established the context of the prior diagnosis.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 lesion in the radiology report, as per EAU guidelines suggesting biopsy for PI-RADS $\ge 3$.
PSA trend shows a clear rising trend from 2.5 ng/mL to 7.0 ng/mL.

AGAINST sampling this patient now
Prior biopsy result was Positive, meaning tissue diagnosis is already established.

WHERE THIS LEANS
LEAN: defer

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 7.00 ng/mL over 4 points spanning 12 months; velocity +4.50 ng/mL per year; doubling time about 8 months.
PROJECTION at 6 months: 10.3 ng/mL, conformal 95% band 2.9-35.8.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.46
  uncertainty  +/- 0.11 epistemic (95% band 0.24-0.68), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.42  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      DEFER, p(biopsy)=0.46  ('discuss' tier, fusion_full; weight 1.5)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.31  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.45 — carried by weighted panel.
PANEL ANSWER: NO BIOPSY. EXPERT-FUSION carried the most weight ('discuss' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

Confidence the trace model expects here: borderline. Weights it expects: bx=important, fh=noted, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the registrar appear to have addressed all three moderator questions. The `radiology_report` addresses Q2 by stating the comparison is "new." The `psa_trend` addresses Q3 by showing a rise from 2.5 to 7.0 ng/mL. The `previous_notes` addresses Q1 by stating the prior grade was "not recorded." The `laboratory_results` addresses the relevance of PSA density given the PSAD of 0.07.

ALIGNMENT WITH THE PANEL
The retrieved findings do not directly overturn the PANEL-PROTOCOL's answer of NO BIOPSY, as the protocol explicitly states that the "documented prior grade in the opened documents: none recorded," leading to the weighted vote of NO BIOPSY.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the grade (Gleason/ISUP) of the prior biopsy? Answered by `previous_notes`: "not recorded."
Q2. Does the PI-RADS 5 lesion in the radiology report represent a new or larger lesion compared to an earlier study? Answered by `radiology_report`: "COMPARISON: new."
Q3. What is the relevance of the PSA trend in this context? Answered by `psa_trend`: "The trend shows a rise from 2.5 ng/mL (Feb 2024) to 7.0 ng/mL (Feb 2025), indicating a rising trend."

WHAT CARRIES WEIGHT, AND WHY
The most relevant variables according to the EAU guideline context are the PI-RADS score (5, suggesting biopsy per EAU threshold) and the documented prior biopsy status (Positive, suggesting tissue diagnosis is established). The rising PSA trend is also relevant as it indicates disease activity.

MY SUGGESTION TO THE CHAIR
Given that the prior biopsy result is positive, tissue diagnosis is established, which weighs against immediate re-biopsy. However, the PI-RADS 5 and the rising PSA trend align with the EAU guideline suggesting biopsy for high-risk lesions. I suggest deferring the decision pending clarification on the prior biopsy grade, as the panel protocol leans towards deferral due to missing documentation.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: borderline)

76y male, PSA 7.0, PI-RADS 5, prior positive biopsy with unrecorded grade. High PI-RADS 5 and rising PSA suggest progression, but prior grade is not recorded. Decision leans against biopsy due to lack of prior grade documentation, favoring re-imaging in two years with a low threshold for biopsy then.

What carried weight: bx=important, age=important, dre=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
